Strategies for transitioning therapy to aripiprazole from other antipsychotics in schizophrenia;Stratégies pour substituer un psychotrope par l'aripiprazole chez des patients schizophrènes

Annals of Pharmacotherapy

Volumn 46, Issue 7-8, 2012, Pages 1097-1104

  Wisniewski, Christopher S ^a   Robert, Sophie ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antipsychotic; Aripiprazole; Schizophrenia; Switching

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BENZATROPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE;

AKATHISIA; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPRESSION SCALE; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; MONOTHERAPY; NAUSEA AND VOMITING; PATIENT ASSESSMENT; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SIDE EFFECT; SIMPSON ANGUS SCALE OF EXTRAPYRAMIDAL SYMPTOM; SUBJECTIVE WELL BEING UNDER NEUROLEPTIC SHORT VERSION JAPANESE EDITION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

ANTIPSYCHOTIC AGENTS; HUMANS; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA;

EID: 84864745929     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q700     Document Type: Article

References (22)

1. Prescribing information. Aripiprazole (Abilify). Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd., February 2011
2. Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother 2003;37:687-694. doi: 10.1345/aph.1C297
3. Komossa K, Rummel-Kluge C, Schmid F, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009;4:CD006569. doi: 10.1002/14651858.CD006569.pub3
4. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 2001;62:923-924. doi: 10.4088/JCP.v62n1201
5. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-389. doi: 10.1124/jpet.102.033175
6. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-136. doi: 10.1016/S0920-9964(03)00050-1
7. Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther 2010;32(suppl 1):S3-S21. doi: 10.1016/j.clinthera.2010.01.021
8. Spurling RD, Lamberti JS, Olsen D, Tu X, Tang W. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry 2007; 68:406-409. doi: 10.4088/JCP.v68n0308
9. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003;166:391-399.
10. Ryckmans V, Kahn JP, Modell S, et al. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. Pharmacopsychiatry 2009;42:114-121. doi: 10.1055/s-0028-1112134
11. Travis MJ, Burns T, Dursun S, et al. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract 2005;59:485-495. doi: 10.1111/j.1368-5031.2005.00498.x
12. Cassano GB, Fagiolini A, Lattanzi L, et al. Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy. Clin Drug Invest 2007;27:1-13. doi: 10.2165/00044011-200727010-00001
13. Sullivan G, Bienroth M, Jones M, Millar H, Ratna L, Taylor D. Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. Curr Med Res Opin 2007;23: 1733-1744. doi: 10.1185/030079907X210633
14. Fagiolini A. Practical guidance for prescribing with aripiprazole in bipolar disorder. Curr Med Res Opin 2008;24:2691-2702. doi: 10.1185/03007990802341426
15. Aitchison KJ, Bienroth M, Cookson J, et al. A UK consensus on the administration of aripiprazole for the treatment of mania. J Psychopharmacol 2009;23:231-240. doi: 10.1177/0269881108098820
16. Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry 2007; 68(suppl 6):10-13.
17. Ramaswamy S, Vijay D, William M, Sattar SP, Praveen F, Petty F. Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol 2004;19: 45-8. doi: 10.1097/00004850-200401000-00009
18. Moeller KE, Shireman TI, Liskow BI. Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. J Clin Psychiatry 2006;67:1942-1947. doi: 10.4088/JCP.v67n1215
19. Takeuchi H, Suzuki T, Uchida H, et al. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. J Clin Psychopharmacol 2008;28:540-543. doi: 10.1097/JCP.0b013e3181842586
20. Pae CU, Serretti A, Chiesa A, et al. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. Eur Neuropsychopharmacol 2009;19:562-570. doi: 10.1016/j.euroneuro.2009.04.002
21. Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011;168:947-956. doi: 10.1176/appi.ajp.2011.10111609
22. Ganguli R, Brar JS, Garbut R, Chang CCH, Basu R. Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. Clin Schizophr Relat Psychoses 2011;5:75-79. doi: 10.3371/CSRP.5.2.3